PMID- 33870112
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 2587-0831 (Print)
IS  - 2587-0831 (Electronic)
VI  - 17
IP  - 2
DP  - 2021 Apr
TI  - Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response 
      to Neoadjuvant Chemotherapy.
PG  - 128-136
LID - 10.4274/ejbh.galenos.2021.2021-2-9 [doi]
AB  - OBJECTIVE: The interpretation of human epidermal growth factor receptor 2 (HER2) 
      fluorescence in situ hybridization (FISH) results may be challenging in tumors 
      with polysomy 17, which is defined as increased signals of chromosome enumeration 
      probe 17 (CEP17). The effect of polysomy 17 on HER2 protein expression and tumor 
      treatment response has not been established. In this retrospective study, we 
      investigated the clinicopathological features of breast cancer with polysomy 17 
      and determined the tumors' response to neoadjuvant chemotherapy (NACT). MATERIALS 
      AND METHODS: The study included 366 patients with primary breast cancer whose 
      tumors had a CEP17 count of >/= three/nucleus based on HER2 FISH studies. These 
      cases were categorized according to HER2/CEP17 ratio and HER2 signals/nucleus 
      using the American Society of Clinical Oncology/College of American Pathologists 
      (ASCO/CAP) guidelines. We compared the clinicopathological characteristics and 
      tumor response to NACT among different groups. RESULTS: There was a statistically 
      significant difference in patients' age at diagnosis, tumor pathological grade, 
      estrogen and progesterone receptor status, and NACT response among different HER2 
      FISH groups. Polysomy 17 tumors in group 1 had a higher rate of response 
      (pathological complete response and residual cancer burden class I) to NACT 
      containing anti-HER2 reagent than did those in other groups (p = 0.004), whereas 
      polysomy 17 tumors in group 3 did not show a significant response to anti-HER2 
      treatment. CONCLUSION: Polysomy 17 tumors in different HER2 FISH groups have 
      different pathological features and respond to NACT differently. These results 
      may help us identify patients who will benefit from anti-HER2 therapy.
CI  - (c)Copyright 2021 by Turkish Federation of Breast Diseases Associations.
FAU - Sun, Hongxia
AU  - Sun H
AUID- ORCID: 0000-0003-3229-4173
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Chen, Hui
AU  - Chen H
AUID- ORCID: 0000-0002-5847-0561
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Crespo, James
AU  - Crespo J
AUID- ORCID: 0000-0003-4891-6133
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas.
FAU - Tang, Guilin
AU  - Tang G
AUID- ORCID: 0000-0002-9482-4806
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Robinson, Melissa
AU  - Robinson M
AUID- ORCID: 0000-0001-9134-8632
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Lim, Bora
AU  - Lim B
AUID- ORCID: 0000-0002-4182-6058
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas.
FAU - Sahin, Aysegul A
AU  - Sahin AA
AUID- ORCID: 0000-0001-8259-9624
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
LA  - eng
PT  - Journal Article
DEP - 20210331
PL  - Turkey
TA  - Eur J Breast Health
JT  - European journal of breast health
JID - 101709357
PMC - PMC8025723
OTO - NOTNLM
OT  - HER2 FISH study
OT  - Polysomy 17
OT  - breast cancer
OT  - neoadjuvant chemotherapy
COIS- Conflict of Interest: No conflict of interest was declared by the authors.
EDAT- 2021/04/20 06:00
MHDA- 2021/04/20 06:01
PMCR- 2021/03/31
CRDT- 2021/04/19 06:40
PHST- 2021/01/21 00:00 [received]
PHST- 2021/02/25 00:00 [accepted]
PHST- 2021/04/19 06:40 [entrez]
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2021/04/20 06:01 [medline]
PHST- 2021/03/31 00:00 [pmc-release]
AID - 47122 [pii]
AID - 10.4274/ejbh.galenos.2021.2021-2-9 [doi]
PST - epublish
SO  - Eur J Breast Health. 2021 Mar 31;17(2):128-136. doi: 
      10.4274/ejbh.galenos.2021.2021-2-9. eCollection 2021 Apr.